A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

Cheolmin Kim, Dong Kyun Ryu, Jihun Lee, Young Il Kim, Ji Min Seo, Yeon Gil Kim, Jae Hee Jeong, Minsoo Kim, Jong In Kim, Pankyeom Kim, Jin Soo Bae, Eun Yeong Shim, Min Seob Lee, Man Su Kim, Hanmi Noh, Geun Soo Park, Jae Sang Park, Dain Son, Yongjin An, Jeong No LeeKi Sung Kwon, Joo Yeon Lee, Hansaem Lee, Jeong Sun Yang, Kyung Chang Kim, Sung Soon Kim, Hye Min Woo, Jun Won Kim, Man Seong Park, Kwang Min Yu, Se Mi Kim, Eun Ha Kim, Su Jin Park, Seong Tae Jeong, Chi Ho Yu, Youngjo Song, Se Hun Gu, Hanseul Oh, Bon Sang Koo, Jung Joo Hong, Choong Min Ryu, Wan Beom Park, Myoung don Oh, Young Ki Choi, Soo Young Lee

Research output: Contribution to journalArticlepeer-review

179 Citations (Scopus)


Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal antibodies (mAb) targeting the receptor binding domain (RBD) of the viral spike protein via antibody library constructed from peripheral blood mononuclear cells of a convalescent patient. The CT-P59 mAb potently neutralizes SARS-CoV-2 isolates including the D614G variant without antibody-dependent enhancement effect. Complex crystal structure of CT-P59 Fab/RBD shows that CT-P59 blocks interaction regions of RBD for angiotensin converting enzyme 2 (ACE2) receptor with an orientation that is notably different from previously reported RBD-targeting mAbs. Furthermore, therapeutic effects of CT-P59 are evaluated in three animal models (ferret, hamster, and rhesus monkey), demonstrating a substantial reduction in viral titer along with alleviation of clinical symptoms. Therefore, CT-P59 may be a promising therapeutic candidate for COVID-19.

Original languageEnglish
Article number288
JournalNature communications
Issue number1
Publication statusPublished - 2021 Dec 1

Bibliographical note

Funding Information:
This study was supported by a Korea National Institute of Health fund (2020-ER5311-00, 2020-ER5323-00, 2019-NI-077-01, 2019-NG-044-01), grants (011555-012664201) from the Agency for Defense Development, grants (PRM1752011) from the Ministry of Science and ICT, and partially supported by the Korea Research Institute of Bioscience and Biotechnology (KRIBB) Research Initiative Program (KGM9942011 and KGM4572013), Republic of Korea.

Funding Information:
Patents have been filed for CT-P59. C.K., D.K.R., J.L., J.M.S., M.K., J.I.K., P.K., J.S.B., E.Y.S., M.S.L., M.S.K., H.N., G.S.P., J.S.P., D.S., Y.A., J.N.L., K.S.K., and S.Y.L. are employees of Celltrion, Inc. This work was funded by Celltrion, Inc. and several grants listed in Acknowledgements. The remaining authors declare no competing interests.

Publisher Copyright:
© 2021, The Author(s).

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)


Dive into the research topics of 'A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein'. Together they form a unique fingerprint.

Cite this